

PHARMACEUTICAL 2022

Propanc Biopharma Inc. Rank 459 of 466







## Propanc Biopharma Inc. Rank 459 of 466

The relative strengths and weaknesses of Propanc Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Propanc Biopharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 676% points. The greatest weakness of Propanc Biopharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 347% points.

The company's Economic Capital Ratio, given in the ranking table, is -491%, being 569% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	6.6
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,081
Liabilities, Non-Current	0
Other Assets	2.2
Other Compr. Net Income	-574
Other Expenses	-85
Other Liabilities	0
Other Net Income	-327
Other Revenues	0
Property and Equipment	4.3
Research and Development	231
Selling, General and Administrative Expense	1,553

Output Variable	Value in 1000 USD
Assets	13
Liabilities	3,081
Expenses	1,699
Revenues	0
Stockholders Equity	-3,068
Net Income	-2,026
Comprehensive Net Income	-2,313
Economic Capital Ratio	-491%

